Predictive Markers of Response
Within the Solid Tumors Program, our group has a highly translational research vocation, which makes it possible to discover aspects with direct clinical application in the field of lung cancer, the most common type of cancer worldwide and the main cause of mortality due to malignancies.
Although some subset of lung cancer patients, such as those with EGFR, ALK, B-RAF or ROS-1 alterations are susceptible to personalized treatments, patients with mutations in KRAS oncogene, the most frequently mutated gene in lung adenocarcinoma, still lack efficient therapies. This fact highlights the importance of identifying new molecular targets to this subgroup of patients and biomarkers able to provide prognostic information of survival and predict the response to different treatments. For the identification and validation of these biomarkers we use different approaches such as bioinformatics analysis using data from clinical databases, functional genomic techniques, murine and human cell lines, genetic and humanized murine models as well as xenograft and metastatic models. Cutting-edge image technologies are also employed to monitor tumor appearance and growth such as luminescence, micro-PET, micro-MRI and micro-CT scans. Moreover, the laboratory has recently incorporated a line of research focused on lung cancer immunotherapy based on the combination of novel compounds against different targets with anti-PD1 antibodies, to improve response rate and survival of subjects with lung cancer. In this area, our group is interested in elucidating the mechanisms associated with response and resistance to immunotherapeutic combined treatments by studying the different cellular populations of the immune system in the tumor microenvironment by means of immunohistochemistry, flow cytometry and/or multiplex techniques.
Finally, we are also working on different liquid biopsy approaches, validating the prognostic and predictive value of the count of Circulating Tumor Cells (CTCs) at onset and the count changes during cancer treatment in patients diagnosed with stage IV adenocarcinoma of the lung. In the laboratory, we also intend to study CTCs at the molecular level and try to generate CDXs models isolating these cells directly from the patients' blood, after informed consent is provided. The Clinical Research Ethics Committee and the Animal Research Ethics Committee, respectively approve each research project with human samples and animal models.
Fecha de actualización: Noviembre 2018